Abstract:Alzheimer's disease (AD) is a chronic neurodegenerative, and abnormal aggregation of the neurotoxic beta amyloid (A beta) peptide is an early event in AD. The present study aimed to determine the correlation between the nicotinic acetylcholine receptor alpha 7 subunit (alpha 7 nAChR) and A beta in the brains of patients with AD, and to investigate whether the increased expression levels of the alpha 7 nAChR could alter the neurotoxicity of A beta. The expression levels of alpha 7 nAChR and A beta in the brains of patients with AD and healthy brains were analyzed using immunofluorescence. Moreover, SH-SY5Y cells were used to stably overexpress or silence alpha 7 nAChR expression levels, prior to the treatment with or without 1 mu mol/l A beta(1-42) oligomer (A beta O). The mRNA and protein expression levels of alpha 7 nAChR, synaptophysin (SYP), postsynaptic density of 95 kDa (PSD-95) and synaptosomal-associated protein of 25 kDa (SNAP-25) were subsequently analyzed using reverse transcription-quantitative PCR and western blotting. In addition, the concentration of acetylcholine (ACh) and the activity of acetylcholinesterase (AChE) were analyzed using spectrophotometry, while the cell apoptotic rate was determined using flow cytometry. The expression of A beta in the brains of patients with AD was found to be significantly increased, whereas the expression of alpha 7 nAChR was significantly decreased compared with the healthy control group. In vitro, the expression levels of alpha 7 nAChR were significantly increased or decreased following the overexpression or silencing of the gene, respectively. Consistent with these observations, the mRNA and protein expression levels of SYP, PSD-95 and SNAP-25 were also significantly increased following the overexpression of alpha 7 nAChR and decreased following the genetic silencing of the receptor. In untransfected or negative control cells, the expression levels of these factors and the apoptotic rate were significantly reduced following the exposure to A beta O, which was found to be attenuated by alpha 7 nAChR overexpression, but potentiated by alpha 7 nAChR RNA silencing. However, no significant differences were observed in either the ACh concentration or AChE activity following transfection. Collectively, these findings suggested that alpha 7 nAChR may protect the brains of patients with AD against A beta, as alpha 7 nAChR overexpression increased the expression levels of SYP, SNAP-25 and PSD-95, and attenuated the inhibitory effect of A beta on the expression of these synaptic proteins and cell apoptosis. Overall, this indicated that alpha 7 nAChR may serve an important neuroprotective role in AD.

Influence of cholesterol and lovastatin on α-form of secreted amyloid precursor protein and expression of α7 nicotinic receptor on astrocytes

Effects of statins on α7 nicotinic receptor, cholinesterase and α-form of secreted amyloid precursor peptide in SH-SY5Y cells

Protection against the Neurotoxic Effects of β-Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of α7 Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases.

Preventing Expression of the Nicotinic Receptor Subunit α7 in SH-SY5Y Cells with Interference RNA Indicates that this Receptor may Protect Against the Neurotoxicity of Aβ

Preventing Expression Of The Nicotinic Receptor Subunit Alpha 7 In Sh-Sy5y Cells With Interference Rna Indicates That This Receptor May Protect Against The Neurotoxicity Of A Beta

Effect of Beta-Amyloid Peptides on Alpha-7 Nicotinic Receptor Status in Astrocytes and Neurons, and Its Relationship to Pathogenesis of Alzheimer's Disease

P3–349: Inhibition of Secreted Alpha–app and Enhanced Neurotoxication of Beta–amyloid Peptide by Interference of Nicotinic Receptor Alpha7 Mrna in SH–SY5Y Cells

[Influence of Inhibited Α7 Nicotinic Acetylcholine Receptor Gene Expression on the Production of Β-Amyloid Peptide in SH-SY5Y Cells].

The consequences of reducing expression of the α7 nicotinic receptor by RNA interference and of stimulating its activity with an α7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease

The activation of astrocyticα7 nicotinic receptor inhibitβ-amyloid aggregation

Activation of Α7 Nicotinic Receptor Affects APP Processing by Regulating Secretase Activity in SH-EP1-α7 Nachr-Happ695 Cells

[Influence of Beta-Amyloid Protein and Cholesterol on the Pathological Changes of Alzheimer's Disease and Expression of Nicotinic Acetylcholine Receptors in Rats].

Neuroprotective effects of β7 neuronal acetylcholine receptor and its roles in the pathogenesis of Alzheimer's disease

Influence of APP_(SWE) Transfection on Nicotinic Receptors in Cultured Neuronal Cells

Amyloid Precursor Protein Gene Mutated at Swedish 670/671 Sites in Vitro Induces Changed Expression of Nicotinic Acetylcholine Receptors and Neurotoxicity

Expression levels of the α7 nicotinic acetylcholine receptor in the brains of patients with Alzheimer's disease and their effect on synaptic proteins in SH-SY5Y cells

[Neuroprotective Effects of Alpha7 Neuronal Acetylcholine Receptor and Its Roles in the Pathogenesis of Alzheimer's Disease].

Inhibiting Gene Expression of Α3 Nicotinic Receptor in SH-SY5Y Cells with the Effects on APP Metabolism and Antioxidation in Alzheimer's Disease

Influence of inhibiting α7 neuronal nicotinic acetylcholine receptor mRNA on lipid peroxidation in SH-SY5Y cells

Lovastatin may up-regulate expression of muscarinic acetylcholine receptors and against the neurotoxicity of β-amyloid peptide on the receptors

Expression levels of the 7 nicotinic acetylcholine receptor in the brains of patients with Alzheimer's disease and their effect on synaptic proteins in SH-SY5Y cells